Mitochondrial gene profiling: Translational perspectives

Pharmacogenomics

Volumn 10, Issue 10, 2009, Pages 1645-1655

  Johnston, Daniel S ^a   Su, Yan A ^b,c   Alesci, Salvatore ^a  

^a PFIZER INC   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c GenProMarkers Inc   (United States)

Author keywords

Gene expression; Microarray; Mitochondria; Translational medicine

Indexed keywords

GLUCOCORTICOID; LAMIVUDINE PLUS ZIDOVUDINE; MITOCHONDRIAL DNA; PROTEIN P53; REACTIVE OXYGEN METABOLITE; ZIDOVUDINE;

DISEASE MARKER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DNA MICROARRAY; DNA SEQUENCE; DNA TRANSCRIPTION; DOSE RESPONSE; DRUG SAFETY; GENE EXPRESSION PROFILING; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRIAL GENE; MYOPATHY; NEUROLOGIC DISEASE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION;

GENE EXPRESSION PROFILING; GENES, MITOCHONDRIAL; GENOMICS; HUMANS; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 70649111384     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.112     Document Type: Review

References (69)

1. Scheffler IE: A century of mitochondrial research: achievements and perspectives. Mitochondrion 1, 3-31 (2001).
2. Clayton DA: Replication and transcription of vertebrate mitochondrial DNA. Annu. Rev. Cell Biol. 7, 453-478 (1991).
3. Graff C, Clayton DA, Larsson N-G: Mitochondrial medicine - recent advances. J. Int. Med. 246, 11-23 (1999). (Pubitemid 29327348)
4. Anderson S, Bankier AT, Barrell BG et al.: Sequence and organization of the human mitochondrial genome. Nature 290, 457-465 (1981). (Pubitemid 11159074)
5. Shoffner J, Wallace DC: Oxidative phosphorylation diseases. Disorders of two genomes. Adv. Hum. Genet. 19, 267-330 (1990).
6. Richter C, Park JW, Ames BN: Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc. Natl Acad. Sci. USA 85, 6465-6467 (1988). (Pubitemid 18219184)
7. Wallace DC: A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu. Rev. Genet. 39, 359-407 (2005).
8. Newgard BC, McGarry JD: Metabolic coupling factors in pancreatic β-cell signal transduction. Annu. Rev. Biochem. 64, 689-719 (1995).
9. Wallace DC, Ye J, Neckelmann SN, Singh G, Webster KA, Greenberg BD: Sequence analysis of cDNAs for the human and bovine ATP synthase β subunit: mitochondrial DNA genes sustain seventeen times more mutations. Curr. Genet. 12, 81-90 (1987). (Pubitemid 17107387)
10. Chinnery PF: Searching for nuclear-mitochondrial genes. Trends Genet. 19, 60-62 (2003).
11. Van Goethem G, Dermaut B, Lofgren A, Martin J-J, Van Broeckhoven C: Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat. Genet. 28, 211-212 (2001). (Pubitemid 32626018)
12. Nass MMK, Nass S: Intramitochondrial fibers with DNA characteristics: I. Fixation and electron staining reactions. J. Cell Biol. 19, 593-611 (1963).
13. Wallace DC, Singh G, Lott MT et al.: Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 242, 1427-1430 (1988). (Pubitemid 19008070)
14. Holt IJ, Harding AE, Morgan-Hughes JA: Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 331, 717-719 (1988).
15. Servidei S: Mitochondrial encephalomyopathies: gene mutation. Neuromuscul. Disord. 11, 690-695 (2001).
16. Schapira C: Mitochondrial myopathies and encephalomyopathies. Eur. J. Clin. Invest. 29, 886-898 (1999).
17. Zeviani M, Corona P, Nijtmans L, Tiranti V: Nuclear gene defects in mitochondrial disorders. Ital. J. Neurol. Sci. 20, 401-498 (1999).
18. Schapira AHV: Mitochondrial dysfunction in neurodegenerative disorders. Biochim. Biophys. Acta 1366, 225-233 (1998).
19. Kelley DE, He J, Menshikova EV, Ritov VB: Dysfunction of mitochondria in human skeletal muscle in Type 2 diabetes. Diabetes 51, 2944-2950 (2002).
20. Enns GM: The contribution of mitochondria to common disorders. Mol. Genet. Metab. 80, 11-26 (2003).
21. Osiewacz HD: Mitochondrial functions and aging. Gene 286, 65-71 (2002).
22. Wang B, Rennert O, Su Y: Mitochondrial oxidative phosphorylation obesity and diabetes. Cell Sci. Rev. 4, 57-81 (2008).
23. DiMauro S, Tanji K, Bonilla E, Pallotti F, Schon EA: Mitochondrial abnormalities in muscle and other aging cells: classification, causes, and effects. Muscle Nerve 26, 597-607 (2002). (Pubitemid 35266083)
24. Szewczyk A, Wojtczak L: Mitochondria as a pharmacological target. Pharmacol. Rev. 54, 101-127 (2002). (Pubitemid 34211027)
25. Johnston DS, Wright WW, DiCandeloro P, Wilson E, Kopf GS, Jelinsky SA: Stage-specific gene expression is a fundamental characteristic of rat spermatogenic cells and Sertoli cells. Proc. Natl Acad. Sci. USA 105, 8315-8320 (2008). (Pubitemid 351904753)
26. Jelinsky SA, Turner TT, Bang HJ et al.: The rat epididymal transcriptome: comparison of segmental gene expression in the rat and mouse epididymides. Biol. Reprod. 76, 561-570 (2007).
27. Alesci S, Su YA, Chrousos GP: Proceedings 17th IEEE Symposium on Computer-Based Medical Systems. IEEE Computer Society Press, CA, USA, 329-334 (2004).
28. Alesci S, Manoli I, Michopoulos VJ et al.: Development of a human mitochondriafocused cDNA microarray (hMitChip) and validation in skeletal muscle cells: implications for pharmaco- and mitogenomics. Pharmacogenomics J. 6, 333-342 (2006). ■ Describes the development and validation of the hMitChip. (Pubitemid 44480153)
29. Bai X, Wu J, Zhang Q et al.: Third-generation human mitochondria-focused cDNA microarray and its bioinformatic tools for analysis of gene expression Biotechniques 42, 365-375 (2007).
30. van der Westhuizen F, van den Heuvel L, Smeets R et al.: Human mitochondrial complex I deficiency: investigating transcriptional responses by microarray. Neuropediatrics 34, 14-22 (2003). (Pubitemid 36457221)
31. Cizkova A, Stranecky V, Ivanek R et al.: Development of a human mitochondrial oligonucleotide microarray (h-MitoArray) and gene expression analysis of fibroblast cell lines from 13 patients with isolated F1Fo ATP synthase deficiency. BMC Genomics 9, 38 (2008). ■■ Describes the developement of the h-MitoArray. (Pubitemid 351359716)
32. Voss J, Raju R, Logun C et al.: A focused microarray to study human mitochondrial and nuclear gene expression. Biol. Res. Nurs. 9, 272-279 (2008).
33. Desai VG, Lee T, Delongchamp RR et al.: Development of mitochondria-specific mouse oligonucleotide microarray and validation of data by real-time PCR. Mitochondrion 7, 322-329 (2007). (Pubitemid 47300171)
34. Subramaniam V, Golik P, Murdock DG et al.: MitoChip assessment of differential gene expression in the skeletal muscle of Ant1 knockout mice: coordinate regulation of OXPHOS, antioxidant, and apoptotic genes. Biochim. Biophys. Acta 1777, 666-675 (2008). ■■ Discusses the use of MitoChip arrays to identify changes in mitochondrial gene expression in Ant1-/- mouse skeletal muscle.
35. Tanaka TS, Jaradat SA, Lim MK et al.: Genome-wide expression profiling of mid-gestation placenta and embryo using a 15,000 mouse developmental cDNA microarray. Proc. Natl Acad. Sci. USA 97, 9127-9132 (2000).
36. Chee M, Yang R, Hubbell E et al.: Accessing genetic information with high-density DNA arrays. Science 274, 610-614 (1996). (Pubitemid 26360440)
37. Maitra A, Cohen Y, SED Gillespie et al.: The human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res. 14, 812-819 (2004). (Pubitemid 38660497)
38. Zhou S, Kassauei K, Cutler DJ et al.: An oligonucleotide microarray for high-throughput sequencing of the mitochondrial genome. J. Mol. Diagn. 8, 476-482 (2006). (Pubitemid 44377930)
39. Divne A, Allen M: A DNA microarray system for forensic SNP analysis. Forensic Sci. Int. 154(2-3), 111-121 (2005). (Pubitemid 41354964)
40. Sigurdsson S, Hedman M, Sistonen P, Sajantila A, Syvänen AC: A microarray system for genotyping 150 single nucleotide polymorphisms in the coding region of human mitochondrial DNA. Genomics 87, 534-542 (2006).
41. Dakubo GD, Parr RL, Jakupciak JP: Prostate cancer: detection and monitoring using mitochondrial mutations as a biomarker. In: General Methods and Overviews, Lung Carcinoma and Prostate Carcinoma. Hayat MA (Ed.). Springer, The Netherlands, 441-464 (2008).
42. Reddy PH, McWeeney S, Park BS et al.: Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum. Mol. Genet. 13, 1225-1240 (2004). (Pubitemid 38877876)
43. Duke D, Moran L, Kalaitzakis M et al.: Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease. Neurogenetics 7, 139-148 (2006). (Pubitemid 44078291)
44. Su YA, Wu J, Zhang L et al.: Dysregulated mitochondrial genes and networks with drug targets in postmortem brain of patients with posttraumatic stress disorder (PTSD) revealed by human mitochondria-focused cDNA microarrays. Int. J. Biol. Sci. 4, 223-235 (2008).
45. Mithani SK, Smith IM, Zhou S et al.: Mitochondrial resequencing arrays detect tumor-specific mutations in salivary rinses of patients with head and neck cancer. Clin. Cancer Res. 13, 7335-7340 (2007).
46. Zhou S, Kachhap S, Sun W et al.: Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc. Natl Acad. Sci. USA 104, 7540-7545 (2007). (Pubitemid 47185942)
47. Wang Q, Ito M, Adams K et al.: Mitochondrial DNA control region sequence variation in migraine headache and cyclic vomiting syndrome. Am. J. Med. Genet. A 131, 50-58 (2004). (Pubitemid 39434794)
48. Di Lorenzo C, Pierelli F, Coppola G et al.: Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology 72, 1588-1594 (2009).
49. Hasselgren PO: Glucocorticoids and muscle catabolism. Curr. Opin. Clin. Nutr. Metab. Care 2, 201-205 (1999).
50. Mitsui T, Azuma H, Nagasawa M et al.: Chronic corticosteroid administration causes mitochondrial dysfunction in skeletal muscle J. Neurol. 249, 1004-1009 (2002). (Pubitemid 35002220)
51. Desai VG, Lee T, Delongchamp RR et al.: Nucleoside reverse transcriptase inhibitors (NRTIs)-induced expression profile of mitochondria-related genes in the mouse liver. Mitochondrion 8, 181-195 (2008).
52. Desai VG, Fuscoe JC: Transcriptional profiling for understanding the basis of mitochondrial involvement in disease and toxicity using the mitochondria-specific MitoChip. Mutat. Res. 616, 210-212 (2007).
53. Feuerstein GZ, Dormer C, Ruffolo RR, Stiles G, Walsh FS, Rutkowski JL: Translational medicine perspectives of biomarkers in drug discovery and development: part I target selection and validation-biomarkers take center stage. Am. Drug Discovery 2, 36-43 (2007).
54. Johnston DS, Robinson JA, Alesci S: Translational medicine approach to osteoporosis drug discovery biomarkers; thinking beyond BMD. Am. Drug Discovery 3, 54-59 (2008).
55. Feuerstein GZ, Rutkowski JL, Walsh FS, Stiles GL, Ruffolo RRJ: The role of translational medicine and biomarker research in drug discovery and development. Am. Drug Discovery 2(1), 23-28 (2006). ■ Overview of biomarker classifications and use in pharmaceutical development.
56. Jakupciak J, Maggrah A, Maragh S et al.: Facile whole mitochondrial genome resequencing from nipple aspirate fluid using MitoChip v2.0. BMC Cancer 8, 95 (2008). (Pubitemid 351676574)
57. Dakubo GD: Mitochondrial genome analysis in biofluids for early cancer detection and monitoring. Expert Opin. Med. Diagn. 2, 263-275 (2008).
58. Sui G, Zhou S, Wang J et al.: Mitochondrial DNA mutations in preneoplastic lesions of the gastrointestinal tract: a biomarker for the early detection of cancer. Mol. Cancer 5, 73 (2006). (Pubitemid 46189687)
59. Rego-Perez I, Fernandez-Moreno M, Fernandez-Lopez C, Arenas J, Blanco F: Mitochondrial DNA haplogroups: role in the prevalence and severity of knee osteoarthritis. Arthritis Rheum. 58, 2387-2396 (2008).
60. Yang Y, Blomme EA, Waring JF: Toxicogenomics in drug discovery: from preclinical studies to clinical trials. Chem. Biol. Interact. 150, 71-85 (2004). (Pubitemid 39441296)
61. de Longueville F, Bertholet V, Remacle J: DNA microarrays as a tool in toxicogenomics. Comb. Chem. High Throughput Screen. 7, 207-211 (2004). (Pubitemid 38737747)
62. Waring JF, Cavet G, Jolly RA et al.: Development of a DNA microarray for toxicology based on hepatotoxin-regulated sequences. EHP Toxicogenomics 111, 53-60 (2003). (Pubitemid 36163313)
63. Waring JF, Gum R, Morfitt D et al.: Identifying toxic mechanisms using DNA microarrays: evidence that an experimental inhibitor of cell adhesion molecule expression signals through the aryl hydrocarbon nuclear receptor. Toxicology 181-182, 537-550 (2002). (Pubitemid 36015749)
64. Yang Y, Abel SJ, Ciurlionis R, Waring JF: Development of a toxicogenomics in vitro assay for the efficient characterization of compounds. Pharmacogenomics J. 7, 177-186 (2006).
65. Leighton JK, Brown P, Ellis A et al.: Workgroup report: review of genomics data based on experience with mock submissions - view of the CDER pharmacology toxicology nonclinical pharmacogenomics subcommittee. Environ. Health Perspect. 114, 573-578 (2006).
66. Coe KJ, Jia Y, Ho HK et al.: Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screening. Chem. Res. Toxicol. 20, 1277-1290 (2007). (Pubitemid 47548296)
67. Washizuka S, Ikeda A, Kato N, Kato T: Possible relationship between mitochondrial DNA polymorphisms and lithium response in bipolar disorder. Int. J. Neuropsychopharmacol. 6, 421-424 (2003). (Pubitemid 38146262)
68. Bai X, Wu J, Zhang Q et al.: Third-generation human mitochondria-focused cDNA microarray and its bioinformatics tools for analysis of gene expression. BioTechniques 42(3), 365-375 (2007).
69. Feuerstein GZ, Dormer C, Ruffolo RR Jr, Stiles G, Walsh FS, Rutkowski JL: Translational medicine perspectives of biomarkers in drug discovery and development: part I target selection and validation - biomarkers take center stage. Am. Drug Discov. 2, 36-43 (2007).